Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04014842 · ClinicalTrials.gov registry record · NA
RapidShock Post-Approval Study
A NA study, sponsored by Zoll Medical Corporation.
- Completed
- Registry status
- NA
- Development phase
- 2,756
- Enrollment target
NCT04014842: Completed NA study, sponsored by Zoll Medical Corporation.
NCT04014842 is a NA study that has completed, run by Zoll Medical Corporation. The registered enrollment target is 2,756 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04014842, a NA study, has completed, sponsored by Zoll Medical Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,756 participants
- Enrollment target
Study Summary
Compare the performance of the Reconfirmation Analysis Mode algorithm to the performance goals recommended by the American Heart Association.
Primary Outcome
Accuracy of the algorithm compared to manual annotation for each rhythm
Interventions
- DEVICE RapidShock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,756 participants |
| Start Date | 2019-02-26 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
What the finished NCT04014842 record still lists
NCT04014842 is an interventional study that assigns participants to a tested intervention. Its 2,756 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% higher).
The record links to 0 conditions, and to 1 intervention - of which RapidShock is the first listed.
NCT04014842 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04014842 about?
NCT04014842 is a clinical study titled "RapidShock Post-Approval Study". Compare the performance of the Reconfirmation Analysis Mode algorithm to the performance goals recommended by the American Heart Association.
What is the current status of trial NCT04014842?
This trial is currently completed. It is a NA study. The enrollment target is 2,756 participants. The study started on 2019-02-26. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04014842?
The interventions under investigation include: RapidShock (DEVICE).
Who is sponsoring clinical trial NCT04014842?
This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04014842's enrollment target sits among peer trials
2,756 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI